KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Consensus "Moderate Buy": Eight analysts rate KalVista an average of "Moderate Buy" (7 buys, 1 sell) with a one‑year average price target of $32.60, versus a recent share price near $19.63, implying notable upside.
• Notable insider selling: Major shareholder Venrock sold 174,645 shares and the CFO sold shares to cover tax withholding, with insiders selling 263,969 shares (~$4.54M) in the past 90 days and now owning 4.30% of the stock.
• Clinical‑stage biotech with clear catalysts: KalVista, market cap about $1.01 billion, is advancing oral and intravitreal plasma kallikrein inhibitors for hereditary angioedema and diabetic macular edema, and trades in a 52‑week range of $9.83–$21.31.

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $32.60.

KALV has been the subject of a number of analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of KalVista Pharmaceuticals in a research report on Tuesday. Stifel Nicolaus boosted their price objective on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a "buy" rating in a research report on Thursday, March 26th. Wall Street Zen downgraded KalVista Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Tuesday, April 21st. HC Wainwright boosted their price objective on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a "buy" rating in a research report on Friday, January 9th. Finally, Needham & Company LLC boosted their price objective on KalVista Pharmaceuticals from $35.00 to $36.00 and gave the stock a "buy" rating in a research report on Wednesday, March 25th.

KalVista Pharmaceuticals Stock Performance

Shares of KalVista Pharmaceuticals stock opened at $19.63 on Friday. KalVista Pharmaceuticals has a one year low of $9.83 and a one year high of $21.31. The company has a market cap of $1.01 billion, a PE ratio of -4.97 and a beta of -0.40. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. The business has a 50-day simple moving average of $17.84 and a 200-day simple moving average of $15.43.

Insider Buying and Selling at KalVista Pharmaceuticals

In related news, major shareholder Venrock Healthcare Capital Par sold 174,645 shares of the company's stock in a transaction that occurred on Wednesday, March 25th. The stock was sold at an average price of $16.95, for a total value of $2,960,232.75. Following the completion of the transaction, the insider directly owned 5,129,340 shares of the company's stock, valued at $86,942,313. This represents a 3.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Brian Piekos sold 1,862 shares of the company's stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $20.22, for a total value of $37,649.64. Following the completion of the transaction, the chief financial officer directly owned 18,150 shares of the company's stock, valued at $366,993. This trade represents a 9.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 263,969 shares of company stock valued at $4,536,178. 4.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KALV. AQR Capital Management LLC acquired a new position in KalVista Pharmaceuticals in the first quarter valued at approximately $646,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in KalVista Pharmaceuticals by 13.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company's stock valued at $281,000 after purchasing an additional 2,939 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in KalVista Pharmaceuticals by 3.7% in the first quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company's stock valued at $3,923,000 after purchasing an additional 12,263 shares in the last quarter. Creative Planning boosted its holdings in KalVista Pharmaceuticals by 20.0% in the second quarter. Creative Planning now owns 33,380 shares of the specialty pharmaceutical company's stock valued at $377,000 after purchasing an additional 5,573 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in KalVista Pharmaceuticals by 2.8% in the second quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company's stock valued at $615,000 after purchasing an additional 1,458 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm's scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista's approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company's lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.